Revance Therapeutics (RVNC) Misses Q4 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/24/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Revance Therapeutic (RVNC) PT Raised to $32 at Goldman Sachs
February 20, 2020 6:09 AM ESTGoldman Sachs analyst Terence Flynn raised the price target on Revance Therapeutic (NASDAQ: RVNC) to $32.00 (from $25.00) while maintaining a Buy rating.... More



